IP Library Granted Patent US 9,669,097
Granted Patent B2
US 9,669,097 · App. 13/823,830 · Granted Jun 6, 2017

Low molecular weight cationic lipids for oligonucleotide delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,669,097
App. No.
13/823,830
Granted
Jun 6, 2017
Kind
B2
Abstract

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

Claims (16)

1. A cationic lipid of Formula A:

wherein:

R 1 and R 2 are each methyl;

R 3 is H;

n is 2;

L 1 is C 12 -C 24 alkenyl; and

L 2 is selected from C 3 -C 9 alkyl and C 3 -C 9 alkenyl;

or any pharmaceutically acceptable salt or stereoisomer thereof.

2. The cationic lipid according to claim 1 which is:

(13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine (Compound 32);

or any pharmaceutically acceptable salt or stereoisomer thereof.

3. A lipid nanoparticle comprising a cationic lipid of claim 1 .

4. The lipid nanoparticle of claim 3 , wherein the lipid nanoparticle further comprises an oligonucleotide.

5. The lipid nanoparticle of claim 4 , wherein the oligonucleotide is siRNA.

6. The lipid nanoparticle of claim 3 , wherein the lipid nanoparticle further comprises cholesterol, DSPC and PEG-DMG.

7. The lipid nanoparticle of claim 3 , wherein the lipid nanoparticle comprises, the cationic lipid (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine (Compound 32), cholesterol, DSPC and PEG-DMG.

Assignments (2)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2014
From: MERCK SHARP & DOHME CORP.
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 032724/0894 →